2020
Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov
Wallach JD, Krystal JH, Ross JS, O’Malley S. Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. JAMA Psychiatry 2020, 77: 1081-1084. PMID: 32459295, PMCID: PMC7254444, DOI: 10.1001/jamapsychiatry.2020.1167.Peer-Reviewed Original Research
2008
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.
Krishnan-Sarin S, O'Malley S, Krystal JH. Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Research 2008, 31: 400-7. PMID: 23584013, PMCID: PMC3860468.Peer-Reviewed Original ResearchConceptsAlcohol dependenceCurrent treatment optionsAlcohol-drinking behaviorDifferent neurochemical systemsAdjunctive treatmentModest efficacyTreatment optionsNew medicationsNew pharmacotherapiesMedicationsHealth problemsNeurochemical systemsPharmacotherapyTreatmentGreat needCertain genesNaltrexoneAlcoholismDisulfiramDrinkers
2007
The NMDA receptor as a therapeutic target in major depressive disorder.
Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS & Neurological Disorders - Drug Targets 2007, 6: 101-15. PMID: 17430148, DOI: 10.2174/187152707780363267.Peer-Reviewed Original ResearchConceptsMajor depressive disorderNMDA receptorsDepressive disorderNovel antidepressant medicationsCognitive side effectsPotential of drugsAntidepressant medicationAntidepressant propertiesSuch medicationsGlutamatergic neurotransmissionGlutamate receptorsPreclinical studiesPsychotomimetic propertiesSide effectsTherapeutic targetAnimal modelsUseful agentNeurotransmissionReceptorsLines of evidenceMedicationsDisordersDrugsCurrent knowledgeDepressionAntiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam
Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. Antiglutamatergic Strategies for Ethanol Detoxification: Comparison With Placebo and Diazepam. Alcohol Clinical And Experimental Research 2007, 31: 604-611. PMID: 17374039, DOI: 10.1111/j.1530-0277.2007.00344.x.Peer-Reviewed Original ResearchConceptsAlcohol withdrawal symptomsWithdrawal symptomsActive medicationAlcohol withdrawalGlutamatergic activationEthanol detoxificationAspartate glutamate receptor antagonistGlutamate release inhibitorGlutamate receptor antagonistsMale alcohol-dependent inpatientsAdditional diazepamDiazepam administrationClinical evidenceStandard pharmacotherapyReceptor antagonistAlcohol-dependent inpatientsRelease inhibitorEthanol dependenceAlcohol abstinenceGlutamate receptorsReceptor inhibitorsWithdrawal severityPlaceboMedicationsNew treatments
2005
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder
Blumberg HP, Donegan NH, Sanislow CA, Collins S, Lacadie C, Skudlarski P, Gueorguieva R, Fulbright RK, McGlashan TH, Gore JC, Krystal JH. Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology 2005, 183: 308-313. PMID: 16249909, DOI: 10.1007/s00213-005-0156-7.Peer-Reviewed Original ResearchConceptsUnmedicated bipolar disorderMood-stabilizing medicationsBipolar disorderBD participantsPotential treatment targetMagnetic resonance imagingPreliminary evidenceMethodsFunctional magnetic resonance imagingAnterior cingulate activationResultsThe groupMedication effectsFunctional abnormalitiesHealthy comparison participantsObjectivesThe aimAnterior cingulateTreatment targetsResonance imagingMedicationsHC participantsAmygdala activationCingulate activationAmygdala increasesComparison participantsEmotional stimuliAbnormalities
2003
A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder
Sierra M, Phillips ML, Ivin G, Krystal J, David AS. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. Journal Of Psychopharmacology 2003, 17: 103-105. PMID: 12680746, DOI: 10.1177/0269881103017001712.Peer-Reviewed Original ResearchConceptsDepersonalization disorderEfficacy of lamotrigineWeeks of treatmentCross-over trialCross-over periodCross-over designDSM-IV depersonalization disorderSole medicationGlutamate releaseLamotriginePatientsCambridge Depersonalization ScaleDisordersTreatmentDepersonalization ScalePlaceboMedicationsHyperactivityRespondersTrialsWeeks
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness
1998
Creatine Kinase Elevations and Aggressive Behavior in Hospitalized Forensic Patients
Hillbrand M, Spitz R, Foster H, Krystal J, Young J. Creatine Kinase Elevations and Aggressive Behavior in Hospitalized Forensic Patients. Psychiatric Quarterly 1998, 69: 69-82. PMID: 9536476, DOI: 10.1023/a:1022137524475.Peer-Reviewed Original ResearchConceptsCK levelsAntipsychotic medicationCreatine kinaseViolent patientsCreatine kinase elevationHigh CK levelsAggressive behaviorProspective studyPatientsClinical diagnosisBiological markersPotential predictorsForensic patientsForensic hospitalMedicationsViolent behaviorSubsequent violenceLevelsHospitalDiagnosisComplications of alcohol withdrawal: pathophysiological insights.
Trevisan LA, Boutros N, Petrakis IL, Krystal JH. Complications of alcohol withdrawal: pathophysiological insights. Alcohol Research 1998, 22: 61-6. PMID: 15706735, PMCID: PMC6761825.Peer-Reviewed Original ResearchConceptsAcute alcohol withdrawalAlcohol withdrawalLong-term sobrietyDelirium tremensAcute withdrawalMental confusionSignificant illnessPathophysiological insightsDisease processPsychiatric problemsCognitive impairmentComplicationsHeavy drinkingMemory disordersWithdrawalDeliriumMedicationsRelapseTremensPatientsSeizuresIllnessImpairmentSeverityHallucinations
1997
Neuroscience: implications for treatment.
Petrakis I, Krystal J. Neuroscience: implications for treatment. Alcohol Research 1997, 21: 157-60. PMID: 15704353, PMCID: PMC6826829.Peer-Reviewed Original Research
1994
ANTIPSYCHOTICS, LITHIUM, BENZODIAZEPINES, BETA-BLOCKERS
Karper L, Bennett A, Erdos J, Krystal J. ANTIPSYCHOTICS, LITHIUM, BENZODIAZEPINES, BETA-BLOCKERS. Journal Of Offender Rehabilitation 1994, 21: 203-222. DOI: 10.1300/j076v21n03_13.Peer-Reviewed Original ResearchPsychiatric patientsCombination of medicationsUse of antipsychoticsTreatment of aggressionAdult psychiatric patientsMethod of administrationPsychiatric manifestationsPsychopharmacologic treatmentAppropriate medicationNeurologic conditionsAggressive patientsPatientsMedicationsDiagnostic assessmentAntipsychoticsTreatmentBenzodiazepinesRelevant literatureCliniciansAdministration
1992
Prolonged postictal encephalopathy in two patients with clozapine- induced seizures
Karper LP, Salloway SP, Seibyl JP, Krystal JH. Prolonged postictal encephalopathy in two patients with clozapine- induced seizures. Journal Of Neuropsychiatry 1992, 4: 454-457. PMID: 1422175, DOI: 10.1176/jnp.4.4.454.Peer-Reviewed Original ResearchBaclofen-assisted detoxification from opiates A pilot study
Krystal J, McDougle C, Kosten T, Price L, Aghajanian G, Charney D. Baclofen-assisted detoxification from opiates A pilot study. Journal Of Substance Use And Addiction Treatment 1992, 9: 139-142. PMID: 1324986, DOI: 10.1016/0740-5472(92)90081-x.Peer-Reviewed Original ResearchConceptsOpen-label pilot studyPilot studyLabel pilot studyOpiate-dependent patientsAbrupt discontinuationOral dosesOpiate detoxificationAdjunctive rolePrimary treatmentOpiate dependencePatientsBaclofenInsufficient suppressionDose rangeMyalgiaVomitingClonidineDiscontinuationMedicationsHeadacheMethadoneDetoxificationDoses
1991
Follow-up Study of Patients With Panic Disorder-Reply
Nagy L, Krystal J, Charney D, Woods S. Follow-up Study of Patients With Panic Disorder-Reply. JAMA Psychiatry 1991, 48: 861-862. DOI: 10.1001/archpsyc.1991.01810330085018.Peer-Reviewed Original ResearchRapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression.
Delgado PL, Price LH, Miller HL, Salomon RM, Licinio J, Krystal JH, Heninger GR, Charney DS. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacology Bulletin 1991, 27: 321-30. PMID: 1775606.Peer-Reviewed Original ResearchConceptsDepressed patientsTRP depletionDesipramine-treated patientsFluvoxamine-treated patientsProvocative challenge testsBrain serotonin contentNeurobiology of depressionMonoamine oxidase inhibitorsMechanism of actionAntidepressant medicationCrossover fashionSerotonin depletionPlasma levelsDepressive relapseSerotonin contentMajor depressionPsychiatric patientsPatientsChallenge testOxidase inhibitorsEssential amino acidsDepressionPercentDaysMedications